← Browse by Condition
Medical Condition

corticosteroid refractory chronic graft vs host disease

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 4
NCT06824103 Phase 4
Recruiting

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

Enrollment
50 pts
Location
China
Sponsor
Novartis Pharmaceuticals
View Trial →